Mark Thompson, PhD, joined Westat in May 2023 as a Vice President for Clinical Research. Thompson is an expert in the areas of real-world data (RWD) and real-world evidence (RWE). He brings over 30 years of experience in clinical research and epidemiology and is an internationally recognized expert in influenza and COVID-19 vaccines. During his distinguished career at the CDC, Thompson was the Principal Investigator on domestic and multi-country investigations of disease burden, immunogenicity, and vaccine effectiveness, including studies focused on pregnant women, infants, older adults, and health care personnel. In addition, he served as Principal Investigator for 2 of CDC’s primary vaccine evaluation platforms during the COVID-19 pandemic.
Prior to joining CDC, Thompson worked at Kaiser Permanente Northern California where he led a clinical practice guidelines initiative. He has also spent time in the private sector developing information technologies and working with large employers, including Ford, General Motors, and AT&T, to improve disease management and preventive care for their employees. Recently, Thompson advised Novavax, Inc., on developing RWD to estimate the effectiveness of Novavax’s COVID-19 vaccine.
- Post-Doctoral Fellowship, Geriatric & Interdisciplinary Medicine, Veterans Administration Medical Center and Stanford University
- Fellowship, Measurement and Statistics, National Institutes of Health
- PhD, Community Psychology and Epidemiology, Indiana University
- Bachelor’s Degree (summa cum laude), Emory University